Literature DB >> 21434652

Chemical and enzyme-assisted syntheses of norbuprenorphine-3-β-D-glucuronide.

Jinda Fan1, Sarah M Brown, Zhude Tu, Evan D Kharasch.   

Abstract

Norbuprenorphine-3-β-d-glucuronide (nBPN-3-β-d-G, 1) is a major phase II metabolite of buprenorphine, a pharmaceutical used for the treatment of opioid addiction. The pharmacological activity of compound 1 is not clear because investigations have been limited by the lack of chemically pure, well characterized 1 in sufficient quantities for in vitro and in vivo experiments. This work describes two concise, new methods of synthesis of 1, a chemical and an enzyme-assisted synthesis. The chemical synthesis used a strategy based on a combination of Koenig-Knorr coupling and amino-silyl protection. The enzyme-assisted synthesis used dog liver to convert the substrate norbuprenorphine (nBPN, 2) to 1. Both methods provided 1, characterized by (1)H NMR and tandem mass spectrometry, with purity >96%. The fractional yield of the enzyme-assisted synthesis was greater than that of the chemical synthesis (67% vs 5.3%), but due to larger reaction volumes, the chemical synthesis afforded greater amounts of total 1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21434652      PMCID: PMC3091394          DOI: 10.1021/bc100550u

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  26 in total

1.  Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite.

Authors:  D Paul; K M Standifer; C E Inturrisi; G W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  1989-11       Impact factor: 4.030

2.  The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry.

Authors:  Wei Huang; David E Moody; Elinore F McCance-Katz
Journal:  Ther Drug Monit       Date:  2006-04       Impact factor: 3.681

3.  Enzyme-assisted synthesis and structural characterization of nitrocatechol glucuronides.

Authors:  L Luukkanen; I Kilpeläinen; H Kangas; P Ottoila; E Elovaara; J Taskinen
Journal:  Bioconjug Chem       Date:  1999 Jan-Feb       Impact factor: 4.774

4.  Hydrolysis of conjugated metabolites of buprenorphine II. The quantitative enzymatic hydrolysis of norbuprenorphine-3-beta-D-glucuronide in human urine.

Authors:  Mahmoud A Elsohly; Waseem Gul; Shixia Feng; Timothy P Murphy
Journal:  J Anal Toxicol       Date:  2005-09       Impact factor: 3.367

5.  Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.

Authors:  Elinore F McCance-Katz; David E Moody; Gene D Morse; Gerald Friedland; Patricia Pade; Jennifer Baker; Anika Alvanzo; Patrick Smith; Abayomi Ogundele; Peter Jatlow; Petrie M Rainey
Journal:  Clin Infect Dis       Date:  2006-12-15       Impact factor: 9.079

6.  Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model.

Authors:  M L Jensen; D Foster; R Upton; C Grant; A Martinez; A Somogyi
Journal:  Xenobiotica       Date:  2007-04       Impact factor: 1.908

7.  The metabolism and excretion of buprenorphine in humans.

Authors:  E J Cone; C W Gorodetzky; D Yousefnejad; W F Buchwald; R E Johnson
Journal:  Drug Metab Dispos       Date:  1984 Sep-Oct       Impact factor: 3.922

8.  Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

Authors:  Elinore F McCance-Katz; David E Moody; Gene D Morse; Qing Ma; Robin DiFrancesco; Gerald Friedland; Patricia Pade; Petrie M Rainey
Journal:  Drug Alcohol Depend       Date:  2007-07-23       Impact factor: 4.492

Review 9.  Buprenorphine maintenance: a new treatment for opioid dependence.

Authors:  Gregory B Collins; Mark S McAllister
Journal:  Cleve Clin J Med       Date:  2007-07       Impact factor: 2.321

10.  The analgesic activity of morphine-6-glucuronide.

Authors:  R Osborne; P Thompson; S Joel; D Trew; N Patel; M Slevin
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

View more
  4 in total

1.  P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception.

Authors:  Sarah M Brown; Scott D Campbell; Amanda Crafford; Karen J Regina; Michael J Holtzman; Evan D Kharasch
Journal:  J Pharmacol Exp Ther       Date:  2012-06-27       Impact factor: 4.030

2.  Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

Authors:  Sarah M Brown; Michael Holtzman; Thomas Kim; Evan D Kharasch
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

Review 3.  Glucuronidated Flavonoids in Neurological Protection: Structural Analysis and Approaches for Chemical and Biological Synthesis.

Authors:  Maite Docampo; Adiji Olubu; Xiaoqiang Wang; Giulio Pasinetti; Richard A Dixon
Journal:  J Agric Food Chem       Date:  2017-08-21       Impact factor: 5.279

4.  Significance of lipid composition in a blood-brain barrier-mimetic PAMPA assay.

Authors:  Scott D Campbell; Karen J Regina; Evan D Kharasch
Journal:  J Biomol Screen       Date:  2013-08-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.